Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Oct 04, 2023 9:05am
125 Views
Post# 35668630

Training, education of doctors/patients, increasing revenues

Training, education of doctors/patients, increasing revenues

https://myhealthywaist.org/

This organization is Quebec based but they participate in various events including conferences in the US, mostly related to obesity and metabolic disorders. Quite encouraging to see these sort of organizations emphasizing/ supporting the importance of dealing with the real issue which isn't general obesity but abdominal fat. The misconception of obesity related health issues (not the visceral fat) among most people only causes the inevitable future medical issues. 

The waist to hip ratio measurement should be considered as the primary diagnostic tool in order to determine whether overweight individuals are at risk of developing various medical conditions including and especially PLWH. The therapeutic benefits of Tesamorelin have been neglected for too long, a trend that has been going on since the launch of the drug despite various studies have been published about the harmful trunk obesity and the metabolic benefits of the drug. I do believe once this misconception is realized we should see much better uptake of the drug . Again it is crucial to have an ongoing thorough training schedule for the sale force/MSLs so they are updated constantly and equipped with evidence based information in order to provide the necessary and appropriate information to the patients and their doctors. One can easily be surprised how clinically outdated both groups have been for too long.

<< Previous
Bullboard Posts
Next >>